Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Pritchard

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The Lancet. Oncology|August 9, 2017
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, David Cunningham, Matthew Nankivell, et al.
Histopathology|December 20, 2024
Diagnostic interobserver variability of atypia assessment in columnar cell lesions among a group of expert breast pathologists in the United Kingdom and the Republic of Ireland, on behalf of the UK national coordinating committee for breast pathologySoha El Sheikh, Mohamed A Mansour, Elena Provenzano, et al.
Breast (Edinburgh, Scotland)|July 7, 2023
Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland -on behalf of the UK national coordinating committee for breast pathologyMohamed Zaakouk, Cecily Quinn, Elena Provenzano, et al.
Nature|November 5, 2025
Anti-progestin therapy targets hallmarks of breast cancer riskBruno M Simões, Robert Pedley, Curtis W McCloskey, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The Lancet. Oncology|August 9, 2017
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, David Cunningham, Matthew Nankivell, et al.
Histopathology|December 20, 2024
Diagnostic interobserver variability of atypia assessment in columnar cell lesions among a group of expert breast pathologists in the United Kingdom and the Republic of Ireland, on behalf of the UK national coordinating committee for breast pathologySoha El Sheikh, Mohamed A Mansour, Elena Provenzano, et al.
Breast (Edinburgh, Scotland)|July 7, 2023
Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland -on behalf of the UK national coordinating committee for breast pathologyMohamed Zaakouk, Cecily Quinn, Elena Provenzano, et al.
Nature|November 5, 2025
Anti-progestin therapy targets hallmarks of breast cancer riskBruno M Simões, Robert Pedley, Curtis W McCloskey, et al.
Pageof 3